ENVB — Enveric Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $3.64m
- -$2.71m
- 17
- 47
- 11
- 14
Annual cashflow statement for Enveric Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.03 | -6.86 | -49 | -18.5 | -17.3 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.818 | 3.22 | 35.7 | 1.21 | 3.03 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.74 | -0.369 | 1.19 | -0.218 | -0.175 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.45 | -3.89 | -11.5 | -17.1 | -14.1 |
| Capital Expenditures | -0.084 | — | -0.865 | -0.584 | -0.005 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.2 | -0.044 | 3.06 | 0 | 0.017 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.284 | -0.044 | 2.19 | -0.584 | 0.012 |
| Financing Cash Flow Items | — | 3.37 | 0 | 0.958 | -0.291 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.8 | 5.53 | 24.9 | 18.2 | -1.34 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.94 | 1.53 | 15.8 | 0.368 | -15.4 |